Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Rare Tumor × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1587 Neoplasms 1338 Carcinoma, Non-Small-Cell Lung 920 Prostatic Neoplasms 860 Colorectal Neoplasms 773 Lung Neoplasms 700 Pancreatic Neoplasms 522 Carcinoma, Hepatocellular 481 Leukemia, Myeloid, Acute 473 Stomach Neoplasms 452 Ovarian Neoplasms 449 Neoplasm Metastasis 430 Multiple Myeloma 427 Recurrence 358 Melanoma 345 Uterine Cervical Neoplasms 327 Squamous Cell Carcinoma of Head and Neck 320 Head and Neck Neoplasms 314 Brain Neoplasms 309 Esophageal Neoplasms 297 Lymphoma 285 Precursor Cell Lymphoblastic Leukemia-Lymphoma 282 Endometrial Neoplasms 275 Triple Negative Breast Neoplasms 262 Rectal Neoplasms 258 Urinary Bladder Neoplasms 248 Glioblastoma 246 Sarcoma 234 Carcinoma, Renal Cell 234 Hematologic Neoplasms 231

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡